PROTALIX BIOTHERAPEUTICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Aharon Schwartz, Ph.D.

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Aharon Schwartz, Ph.D.”): 20,105,843 for, 7,227,362 withheld, per its Form 8-K filed June 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 591,889 for, 2,122,171 withheld, 27,657 abstained.

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Amos Bar Shalev

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Amos Bar Shalev”): 14,916,342 for, 12,416,863 withheld, per its Form 8-K filed June 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 54.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 212,997 for, 2,500,423 withheld, 28,297 abstained.

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Dror Bashan

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dror Bashan”): 22,359,235 for, 4,973,970 withheld, per its Form 8-K filed June 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,737,079 for, 4,638 withheld.

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Eliot Richard Forster, Ph.D.

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Eliot Richard Forster, Ph.D.”): 22,800,329 for, 4,532,876 withheld, per its Form 8-K filed June 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,742,220 for.

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Gwen A. Melincoff

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Gwen A. Melincoff”): 22,884,691 for, 4,448,514 withheld, per its Form 8-K filed June 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,737,079 for, 4,638 withheld.

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Pol F. Boudes, M.D.

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Pol F. Boudes, M.D.”): 22,866,402 for, 4,466,803 withheld, per its Form 8-K filed June 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,737,079 for, 4,638 withheld.

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Shmuel "Muli" Ben Zvi, Ph.D.

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Shmuel "Muli" Ben Zvi, Ph.D.”): 22,781,806 for, 4,551,399 withheld, per its Form 8-K filed June 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,737,079 for, 4,638 withheld.

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Aharon Schwartz, Ph.D.

The 5 asset managers below reported 1,152 for, 1,962 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Amos Bar Shalev

The 5 asset managers below reported 2,604 withheld, 510 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Dror Bashan

The 5 asset managers below reported 3,114 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Gwen A. Melincoff

The 5 asset managers below reported 3,114 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Pol F. Boudes, M.D.

The 5 asset managers below reported 3,114 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Shmuel "Muli" Ben Zvi, Ph.D.

The 5 asset managers below reported 3,114 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected: Zeev Bronfeld

The 5 asset managers below reported 1,152 for, 1,962 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 144,000,000 to 185,000,000; and

The 5 asset managers below reported 3,114 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 12,475,171 shares to 17,475,171 shares and to amend certain other terms of said plan;

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“3. Adoption of amendments to the Protalix BioTherapeutics, Inc”): 16,905,530 for, 10,341,645 against — passed, per its Form 8-K filed June 28, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) adopted amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), available under such plan from 12,475,171 shares to 17,475,171 shares and adopted cert…”
Support: 62% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,737,582 for, 4,638 against.

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Description as filed by funds: To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan;

The 5 asset managers below reported 3,114 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement that accompanies this notice;

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“2. Approval, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 17,038,394 for, 9,884,021 against — passed, per its Form 8-K filed June 28, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 31 managers: 2,569,570 for, 172,650 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports, all 47 managers: 3,356,571 for, 263,330 against. Showing the 25 largest; every one is in the interactive database (link above).

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement that accompanies this notice.

The 27 asset managers below reported 889,597 for, 2 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: To approve, on a non-binding advisory basis, on the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company's named executive officers;

The 16 asset managers below reported 347,530 1 year.

Description as filed by funds: To approve, on a non-binding advisory basis, on the frequency that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company's named executive officers

The 15 asset managers below reported 281,609 against, 261,319 1 year. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2024

PROTALIX BIOTHERAPEUTICS INC.’s own tally for this item (“4. Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fisc”): 37,489,163 for, 3,872,560 against — passed, per its Form 8-K filed June 28, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) ratified the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares present or represented (“majority of the shares present”).

The 32 asset managers below reported 2,752,320 for.

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Description as filed by funds: To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2023;

The 5 asset managers below reported 3,114 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.